# Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis

> **NCT05642468** · PHASE2 · TERMINATED · sponsor: **Albireo, an Ipsen Company** · enrollment: 18 (actual)

## Conditions studied

- Primary Sclerosing Cholangitis

## Interventions

- **DRUG:** Ritivixibat

## Key facts

- **NCT ID:** NCT05642468
- **Lead sponsor:** Albireo, an Ipsen Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2023-01-09
- **Primary completion:** 2025-07-10
- **Final completion:** 2025-07-10
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Due to Sponsor decision, not due to any safety concerns
- **Last updated:** 2026-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05642468

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05642468, "Safety and Tolerability of A3907 in Primary Sclerosing Cholangitis". Retrieved via MORVS 2026-10-13 from https://api.morvs.ai/clinical/NCT05642468. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*